Baimas-George Maria, Watson Michael, Murphy Keith J, Sarantou John, Vrochides Dionisios, Martinie John B, Baker Erin H, Mckillop Iain H, Iannitti David A
Division of Hepato-Pancreato-Biliary Surgery, Department of Surgery, Carolinas Medical Center, Atrium Health, Charlotte, NC, USA.
Division of Hepato-Pancreato-Biliary Surgery, Department of Surgery, Carolinas Medical Center, Atrium Health, Charlotte, NC, USA.
HPB (Oxford). 2021 Mar;23(3):444-450. doi: 10.1016/j.hpb.2020.08.001. Epub 2020 Sep 29.
Ruptured, or bleeding, hepatocellular carcinoma (rHCC) is a relatively rare disease presentation associated with high acute mortality rates. This study sought to evaluate outcomes following laparoscopic microwave ablation (MWA) and washout in rHCC.
A retrospective single-center review was performed to identify patients with rHCC (2008-2018). The treatment algorithm consisted of transarterial embolization (TAE) or trans-arterial chemoembolization (TACE) followed by laparoscopic MWA and washout.
Fifteen patients with rHCC were identified (n = 5 single lesion, n = 5 multifocal disease, n = 5 extrahepatic metastatic disease). Median tumor size was 83 mm (range 5-228 mm), and 10 of 15 underwent TAE or TACE followed by laparoscopic MWA/washout. One patient required additional treatment for bleeding after MWA with repeat TAE. Thirty-day mortality was 6/15. For those patients discharged (n = 9), additional treatments included chemotherapy (n = 5), TACE (n = 3), and/or partial lobectomy (n = 2). Median follow-up was 18.2 months and median survival was 431 days (range 103-832) (one-year survival n = 7; two-year survival n = 4; three-year survival n = 3). Six patients had post-operative imaging from which one patient demonstrated recurrence.
Using laparoscopic MWA with washout may offer advantage in the treatment of ruptured HCC. It not only achieves hemostasis but also could have oncologic benefit by targeting local tumor and decreasing peritoneal carcinomatosis risk.
破裂性肝细胞癌(rHCC),即出血性肝细胞癌,是一种相对罕见的疾病表现形式,急性死亡率较高。本研究旨在评估腹腔镜微波消融(MWA)联合冲洗治疗rHCC后的疗效。
进行一项回顾性单中心研究,以确定rHCC患者(2008年至2018年)。治疗方案包括经动脉栓塞(TAE)或经动脉化疗栓塞(TACE),随后进行腹腔镜MWA和冲洗。
共确定15例rHCC患者(单发病灶5例,多灶性疾病5例,肝外转移疾病5例)。肿瘤中位大小为83毫米(范围5 - 228毫米),15例患者中有10例接受了TAE或TACE,随后进行腹腔镜MWA/冲洗。1例患者在MWA后因出血需要再次进行TAE治疗。30天死亡率为6/15。对于出院的患者(9例),额外的治疗包括化疗(5例)、TACE(3例)和/或部分肝叶切除术(2例)。中位随访时间为18.2个月,中位生存期为431天(范围103 - 832天)(1年生存率7例;2年生存率4例;3年生存率3例)。6例患者有术后影像学检查,其中1例显示复发。
使用腹腔镜MWA联合冲洗治疗破裂性肝癌可能具有优势。它不仅能实现止血,还可能通过靶向局部肿瘤和降低腹膜种植转移风险而具有肿瘤学益处。